stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Precision Neuroscience Corporation

United States · Privately owned

Precision Neuroscience makes thin, flexible electrode films that sit on the surface of the brain to help doctors monitor and treat neurological conditions.

Precision Neuroscience is a medical device company building a new kind of brain implant. Its main product is the Layer 7 Cortical Interface, a thin, flexible film covered in tiny electrodes that a surgeon lays on the surface of the brain. The film is designed to read the electrical signals brain cells use to communicate, letting doctors and researchers see what the brain is doing in real time.

The core problem it solves is that the brain is soft and delicate, while older electrode arrays tend to be stiff and invasive. Precision's film is about the thickness of a sheet of paper and is designed to sit on the brain without damaging it. The company's most dramatic claim is that the device can be placed and removed through a slit in the skull roughly the width of a hair, rather than requiring surgeons to open the skull widely. That could make brain monitoring far less risky and far more practical. Clinicians and researchers are the customers. They would use the arrays to study brain activity and, over time, to help treat conditions like epilepsy and to build brain-computer interfaces—systems that let a paralyzed person control a computer or robotic arm with thought alone. The company is still in the development and early testing stage, so it is not yet a big revenue business. Its bet is that a gentler, minimally invasive electrode will win adoption where bulky implants have struggled.


Precision Neuroscience was founded in 2021 by a team that includes Benjamin Rapoport, a neurosurgeon who was also a co-founder of Neuralink, the better-known brain-implant company backed by Elon Musk. That connection matters: Precision is often described as the more surgical, less flashy cousin in the brain-interface race. Its path to money runs through regulatory approval and hospital adoption, which are slow and uncertain, so the company's future depends on proving its films are safe and useful in real patients.

Saved answer · last researched 16 Nov 2026